Elena Esperanza‐Cebollada

Elena Esperanza‐Cebollada

Auto-generated profile, based on publicly available information

Elena Esperanza‐Cebollada

Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona (PCCB) Institut de Recerca Hospital Sant Joan de Déu Barcelona Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
EEElena Esperanza‐Cebollada
Elena Esperanza‐Cebollada
Soledad Gómez-GonzalezSoledad Gómez-Gonzalez
Soledad Gómez-Gonzalez
SPSara Perez-Jaume
Sara Perez-Jaume
NVNerea Vega-García
Nerea Vega-García
CVClara Vicente‐Garcés
Clara Vicente‐Garcés
MCMireia Camós
Mireia Camós

30 March 2025 in British Journal of Haematology
Verified
Journal Article
Open access
CVClara Vicente‐Garcés
Clara Vicente‐Garcés
GFGuerau Fernández
Guerau Fernández
EEElena Esperanza‐Cebollada
Elena Esperanza‐Cebollada
MRMercè Richarte‐Franqués
Mercè Richarte‐Franqués
ACAlba Crespo‐Carrasco
Alba Crespo‐Carrasco
NVNerea Vega-García
Nerea Vega-García
Summary: B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) comprises multiple subtypes characterized by different genetic alterations. With the use of current standard‐of‐care tests used in clinical practice, 20%–30% of the cases may not be classified into the main genetic subtypes and additional approaches are needed. These patients are grouped in the heterogeneous category B‐other ALL. Transcriptome sequencing (RNA‐seq) has allowed the identification of novel fusion genes and gene expression profiles that define new molecular subtypes. We present RNA‐seq results integrated, in a real‐world scenario, with clinical routine diagnostic data to identify new biomarkers and reclassify a cohort of 60 B‐other ALL patients in the newly described genetic subtypes. Overall, 49 rearrangements were identified, including 32 different fusion genes in 41 B‐other patients (68%). Moreover, we reported six novel rearrangements ( IGK::PAX5 , PAX5::IL1RAPL1 , ETV6::KRT78 , IGH::HIC1 , IGH::MIR100HG and NKAIN4::PNPLA7 ). The integration of RNA‐seq results with standard‐of‐care data allowed us to classify 72% of the patients (43/60) in 11 different subtypes, being DUX4 rearranged and PAX5 alt the most represented subtypes. In summary, RNA‐seq is a reliable tool for the identification of new emerging genetic subtypes contributing to a better genetic risk stratification of BCP‐ALL paediatric patients on the path towards a more personalized medicine.

26 November 2020 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
NVNerea Vega-Garcia
Nerea Vega-Garcia
RBRocio Benito
Rocio Benito
EEElena Esperanza-Cebollada
Elena Esperanza-Cebollada
MLMarta Llop
Marta Llop
CRCristina Robledo
Cristina Robledo
O(on behalf of the Group of Leukemia of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
on behalf of the Group of Leukemia of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.

28 October 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
ATAlexandre Theron
Alexandre Theron
AAAnna Alonso‐Saladrigues
Anna Alonso‐Saladrigues
JDJose‐Luis Dapena
Jose‐Luis Dapena
MLMónica López‐Duarte
Mónica López‐Duarte
CHCristina Diaz de Heredia
Cristina Diaz de Heredia
ACAlbert Català
Albert Català